JanosLTanyiMD

Obstetrics & Gynecology • Philadelphia, PA

Gynecologic Oncology

Assistant Professor, Obstetrics & Gynecology, Perelman School of Medicine

Join to view full profile

Dr. Tanyi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tanyi's full profile

Already have an account?

Office
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-662-3318

Fax+1 215-349-5680

Education & Training

University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
Baylor College of MedicineResidency, Obstetrics and Gynecology, 2004 - 2008
University of Debrecen Medical and Health Science CenterClass of 1993

Certifications & Licensure

PA State Medical License 2008 - 2026
TX State Medical License 2012 - 2026
NJ State Medical License 2021 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Autologous OC-DC Vaccine in Ovarian Cancer Start of enrollment: 2010 May 01
Completed
Early Phase 1
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Start of enrollment: 2011 Mar 01
Terminated
Phase 1
CAR T Cells in Mesothelin Expressing Cancers Start of enrollment: 2017 Apr 06
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from ...
Patrick Wagner, Edward A Levine, Alex C Kim, Perry Shen, Nicole D Fleming
Annals of Surgical Oncology. 2024-07-01
3 citations
Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.
Patrick Wagner, Edward A Levine, Alex C Kim, Perry Shen, Nicole D Fleming
Annals of Surgical Oncology. 2024-07-01
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.
Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang
Biorxiv. 2024-05-21

Lectures

DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian c...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Positive Phase 2 Study Results Published for on Target's Intraoperative Cancer Imaging AgentOctober 15th, 2019
IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free SurvivalJune 1st, 2019
Triggering an Immune Response in Ovarian CancerJuly 12th, 2018
Join now to see all

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow

Other Languages

Hungarian